A randomized subject- and investigator-blinded placebo-controlled pharmacodynamic study of oral LIK066 in overweight and obese women with polycystic ovary syndrome

  • STATUS
    None
Send
Updated on 19 February 2024

Summary

The purpose of the study is to evaluate whether LIK066 can be developed for the treatment of polycystic ovary syndrome (PCOS) in overweight and obese women. Approximately 24 subjects will be randomized in a 1:1 ratio to LIK066 or placebo (12 subjects on LIK066; 12 on placebo). The treatment period is 2 weeks; dosing is oral, 50 mg of LIK066 or matching placebo three times daily before meals for 14 days and a single dose on Day 15 in the morning before the test meal. Each subject will participate in a screening period of up to 6 weeks, a baseline assessment, a treatment period of 2 weeks, and a follow-up period of about 1 week with an end of study visit on approximately Day 22.

Details
Condition TBD, tbd, tbd
Age 99years or below
Clinical Study Identifier03152591
Last Modified on19 February 2024

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.